- Alpelisib - the first PI3K inhibitor in the treatment of hormone-positive, HER2-negative breast cancer2021 | First Faculty of Medicine
- Impact of BOLERO-2 study results on clinical practice and future treatment of postmenopausal patients with advance HR+/HER2- breast cancer2014 | First Faculty of Medicine